Therefore, we hypothesize that effectivity of GSK3-β inhibitors could be enhanced by concomitantly inhibiting Chk1 and such a combined inhibition of Chk1 and GSK3-β might be a more effective treatment against cancer cells (Figure 5C for a model). The gene discussed is GSK3B; the disease is cancer.